دورية أكاديمية
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
| العنوان: | Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study |
|---|---|
| المؤلفون: | Coates, LC, Gladman, DD, Nash, P, FitzGerald, O, Kavanaugh, A, Kvien, TK, Gossec, L, Strand, V, Rasouliyan, L, Pricop, L, Ding, K, Jugl, SM, Gaillez, C |
| بيانات النشر: | BMC |
| سنة النشر: | 2018 |
| المجموعة: | Griffith University: Griffith Research Online |
| مصطلحات موضوعية: | Clinical sciences, Immunology, Health services and systems, Public health, Science & Technology, Life Sciences & Biomedicine, Rheumatology, Psoriatic arthritis, Secukinumab |
| الوصف: | Background: Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psoriatic Arthritis Disease Activity Score (PASDAS)-based remission or low disease activity (LDA) through 2 years among patients with PsA in the FUTURE 2 study. Methods: PASDAS (cut-off scores: remission ≤ 1.9; LDA > 1.9 and < 3.2; Moderate Disease Activity ≥ 3.2 and < 5.4; and high disease activity [HDA] ≥ 5.4) was assessed in the overall population (tumour necrosis factor inhibitor [TNFi]-naïve and TNFi-experienced), in patients stratified by prior TNFi use and by disease duration at weeks 16, 52 and 104. The impact of secukinumab on individual PASDAS core components and on the relationship between PASDAS states and patient-reported outcomes (PROs), including physical function, health-related quality of life (HRQoL) and work productivity, were also assessed. Data for the approved doses of secukinumab (300 and 150 mg) are reported. PASDAS scores and core components were reported as observed, and PROs were analysed using mixed models for repeated measures. Results: In the overall population, PASDAS remission and LDA were achieved in 15.6% and 22.9%, respectively, of patients treated with secukinumab 300 mg and in 15.2% and 19.2%, respectively, in the secukinumab 150 mg group versus 2.3% and 13.8%, respectively, with placebo at week 16. In the TNFi-naïve group, a higher proportion of patients achieved remission + LDA at week 16 with secukinumab 300 and 150 mg (46.2% and 42.9%, respectively) versus placebo (17.5%), with corresponding responses in TNFi-experienced patients being 22.6% and 19.4% versus 13.3%. Remission/LDA responses with secukinumab were sustained through 2 years. Patients achieving remission/LDA reported greater improvements in PROs than patients in HDA through 2 years. Conclusions: Secukinumab-treated patients achieved higher PASDAS-defined remissions or ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1478-6354 |
| العلاقة: | Arthritis Research & Therapy; Coates, LC; Gladman, DD; Nash, P; FitzGerald, O; Kavanaugh, A; Kvien, TK; Gossec, L; Strand, V; Rasouliyan, L; Pricop, L; Ding, K; Jugl, SM; Gaillez, C, Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study, Arthritis Research & Therapy, 2018, 20 (1), pp. 272; http://hdl.handle.net/10072/399818Test |
| DOI: | 10.1186/s13075-018-1773-y |
| الإتاحة: | https://doi.org/10.1186/s13075-018-1773-yTest http://hdl.handle.net/10072/399818Test |
| حقوق: | http://creativecommons.org/licenses/by/4.0Test/ ; © The Author(s). 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0Test/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0Test/) applies to the data made available in this article, unless otherwise stated ; open access |
| رقم الانضمام: | edsbas.9B795CB2 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14786354 |
|---|---|
| DOI: | 10.1186/s13075-018-1773-y |